Modality
Fusion Protein
MOA
JAK1i
Target
GPRC5D
Pathway
Notch
IPFHCC
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
→ Dec 2030
Phase 2Current
NCT04419139
491 pts·IPF
2023-11→TBD·Terminated
NCT05933492
255 pts·IPF
2018-01→2030-12·Completed
746 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-194mo awayBTD· HCC
2030-12-044.7y awayPh3 Readout· IPF
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Complet…
P2/3
Termina…
Catalysts
BTD
2026-07-19 · 4mo away
HCC
Ph3 Readout
2030-12-04 · 4.7y away
IPF
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04419139 | Phase 2/3 | IPF | Terminated | 491 | ACR20 |
| NCT05933492 | Phase 2/3 | IPF | Completed | 255 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |